Claudon, Michel2; Dietrich, Christoph F2; Choi, Byung Ihn2; Cosgrove, David O2; Kudo, Masatoshi2; Nolsøe, Christian P1; Piscaglia, Fabio2; Wilson, Stephanie R2; Barr, Richard G2; Chammas, Maria C2; Chaubal, Nitin G2; Chen, Min-Hua2; Clevert, Dirk Andre2; Correas, Jean Michel2; Ding, Hong2; Forsberg, Flemming2; Fowlkes, J Brian2; Gibson, Robert N2; Goldberg, Barry B2; Lassau, Nathalie2; Leen, Edward L S2; Mattrey, Robert F2; Moriyasu, Fuminori2; Solbiati, Luigi2; Weskott, Hans-Peter2; Xu, Hui-Xiong2
1 Gastroenterology, Herlev and Gentofte Hospital, The Capital Region of Denmark2 unknown
A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS
Initially, a set of guidelines for the use of ultrasound contrast agents was published in 2004 dealing only with liver applications. A second edition of the guidelines in 2008 reflected changes in the available contrast agents and updated the guidelines for the liver, as well as implementing some non-liver applications. Time has moved on, and the need for international guidelines on the use of CEUS in the liver has become apparent. The present document describes the third iteration of recommendations for the hepatic use of contrast enhanced ultrasound (CEUS) using contrast specific imaging techniques. This joint WFUMB-EFSUMB initiative has implicated experts from major leading ultrasound societies worldwide. These liver CEUS guidelines are simultaneously published in the official journals of both organizing federations (i.e., Ultrasound in Medicine and Biology for WFUMB and Ultraschall in der Medizin/European Journal of Ultrasound for EFSUMB). These guidelines and recommendations provide general advice on the use of all currently clinically available ultrasound contrast agents (UCA). They are intended to create standard protocols for the use and administration of UCA in liver applications on an international basis and improve the management of patients worldwide.
Ultrasound in Medicine and Biology, 2013, Vol 39, Issue 2, p. 187-210